Key insights
- Personalis Inc. (PSNL) stock reached a 52-week high, driven by strong Q1 revenue exceeding estimates and significant growth in its NeXT Personal MRD test. The test's expansion of Medicare coverage and increasing adoption by oncologists are key drivers. Despite analyst price target adjustments, ratings remain positive, reflecting confidence in MRD growth. However, InvestingPro analysis suggests the stock may be overvalued relative to its fair value.
Personalis Inc (PSNL) stock reached a notable milestone, hitting a 52-week high of $11.51. This upward trajectory marks a significant increase in the company’s stock value, which has seen an impressive 144.28% change over the past year. The stock surged nearly 30% in just the past week, with a market capitalization now standing at $1.2 billion. The biotech firm, known for its innovative genomic solutions, has captured investor interest with its robust performance and strategic initiatives. This recent peak underscores a period of strong growth and market confidence in Personalis’ capabilities and future prospects. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate. Investors seeking deeper insights can access PSNL’s comprehensive Pro Research Report, one of 1,400+ available reports that transform complex data into actionable intelligence.
In other recent news, Personalis Inc. reported first-quarter revenue that exceeded consensus estimates, with its NeXT Personal minimal residual disease (MRD) test showing significant growth. The test’s revenue increased by 258% year-over-year and 26% quarter-over-quarter, reaching over 1,000 oncologists who ordered it in the first quarter. The Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program expanded coverage for the NeXT Personal MRD test to include monitoring treatment response for patients with Stage II-III Triple-Negative Breast Cancer, HER2-positive breast cancer, and immunotherapy monitoring for late-stage solid tumors. This marks the company’s fourth Medicare coverage milestone, enhancing its ability to monitor therapy effectiveness before surgery.
BTIG adjusted its price target for Personalis to $11 from $13, maintaining a Buy rating, while Needham reiterated a Buy rating with a $12 price target, citing MRD growth. The company held its 2026 annual meeting virtually, where shareholders elected directors and approved various proposals. The meeting had a significant turnout, with holders of 91,869,300 shares representing 87.76% of the company’s outstanding shares as of the record date. These developments reflect ongoing interest and activity in Personalis’ financial and operational strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.